Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $56.69 Million |
|---|---|
| Enterprise Value | $67.85 Million |
| Earnings per Share | $-1.87 |
| Beta | -0.55 |
| Outstanding Shares | 213,912,821 |
| P/E Ratio | -2.81 |
|---|---|
| PEG | 27.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.27 |
| Enterprise Value to Revenue | 1.7 |
| Enterprise Value to EBIT | -0.24 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.74 |
| Debt to Equity | -20.26 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-dr...